Avid Bioservices, Inc., a biologics contract development and manufacturing company, focuses on the development and current Good Manufacturing Practices (cGMP) manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, cGMP clinical, and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The company produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and offers services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission, and support. It also provides various process development services, such as cell line development and optimization, cell culture and feed optimization, analytical methods development, and product characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CDMO
CUSIPN/A
Phone714-508-6100
Debt
Debt-to-Equity RatioN/A
Current Ratio2.21
Quick Ratio1.86
Price-To-Earnings
Trailing P/E Ratio-11.22
Forward P/E Ratio-23.38
P/E GrowthN/A
Sales & Book Value
Annual Sales$53.62 million
Price / Sales5.86
Cash FlowN/A
Price / CashN/A
Book Value$1.00 per share
Price / Book5.61
Profitability
EPS (Most Recent Fiscal Year)($0.50)
Net Income$-21,810,000.00
Net Margins-57.67%
Return on Equity-60.06%
Return on Assets-34.12%
Miscellaneous
Employees186
Outstanding Shares56,000,000
Market Cap$319.77 million
Avid Bioservices (NASDAQ:CDMO) Frequently Asked Questions
What is Avid Bioservices' stock symbol?
Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."
How often does Avid Bioservices pay dividends? What is the dividend yield for Avid Bioservices?
Avid Bioservices announced a dividend on Wednesday, March 7th. Stockholders of record on Monday, March 19th will be given a dividend of $0.6563 per share on Monday, April 2nd. The ex-dividend date is Friday, March 16th. View Avid Bioservices' Dividend History.
When did Avid Bioservices' stock split? How did Avid Bioservices' stock split work?
Avid Bioservices's stock reverse split on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.
How were Avid Bioservices' earnings last quarter?
Avid Bioservices Inc (NASDAQ:CDMO) issued its earnings results on Monday, September, 10th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.09) by $0.03. The biopharmaceutical company earned $12.59 million during the quarter, compared to the consensus estimate of $9.95 million. Avid Bioservices had a negative return on equity of 60.06% and a negative net margin of 57.67%. View Avid Bioservices' Earnings History.
When is Avid Bioservices' next earnings date?
What price target have analysts set for CDMO?
5 equities research analysts have issued 12-month target prices for Avid Bioservices' shares. Their forecasts range from $4.00 to $11.00. On average, they anticipate Avid Bioservices' stock price to reach $8.3333 in the next twelve months. This suggests a possible upside of 48.5% from the stock's current price. View Analyst Price Targets for Avid Bioservices.
What is the consensus analysts' recommendation for Avid Bioservices?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avid Bioservices.
What are Wall Street analysts saying about Avid Bioservices stock?
Here are some recent quotes from research analysts about Avid Bioservices stock:
- 1. According to Zacks Investment Research, "Avid Bioservices, Inc. is a dedicated contract development and manufacturing organization focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. It also offer process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. Avid Bioservices Inc., formerly known as Peregrine Pharmaceuticals Inc., is based in TUSTIN, United States. " (7/19/2018)
- 2. HC Wainwright analysts commented, "Valuation and impediments to achieving price target. We maintain our Buy rating and are increasing our price target to $6 from $5. Our valuation is based on a discounted EBITDA model, which we believe takes into account both the established and anticipated revenue growth of Avid, which is the cornerstone of the company’s business. We assign a 15x (up from 13x) multiple on F2023 EBITDA discounted back at Avid’s WACC of 13%. Our 15x multiple is based on recent CDMO deals in North America, which ranged from 10-15x for EV/LTM EBITDA." (7/17/2018)
Who are some of Avid Bioservices' key competitors?
Some companies that are related to Avid Bioservices include TherapeuticsMD (TXMD), Tricida (TCDA), Insmed (INSM), Esperion Therapeutics (ESPR), Vanda Pharmaceuticals (VNDA), Arrowhead Pharmaceuticals (ARWR), ImmunoGen (IMGN), Kiniksa Pharmaceuticals (KNSA), Retrophin (RTRX), Intra-Cellular Therapies (ITCI), Uniqure (QURE), CannTrust (CNTTF), Zai Lab (ZLAB), Rhythm Pharmaceuticals (RYTM) and Lexicon Pharmaceuticals (LXRX).
Who are Avid Bioservices' key executives?
Avid Bioservices' management team includes the folowing people:
- Dr. Roger J. Lias, Pres, CEO & Director (Age 58)
- Mr. Mark R. Ziebell, VP, Gen. Counsel & Corp. Sec. (Age 54)
- Mr. Daniel R. Hart, Chief Financial Officer (Age 45)
- Ms. Tracy L. Kinjerski, VP of Bus. Operations
- Mr. Stephen Michael Hedberg, Sr. Director of Fin. & SEC Reporting and Principal Financial & Accounting Officer (Age 43)
Who are Avid Bioservices' major shareholders?
Avid Bioservices' stock is owned by a number of of institutional and retail investors. Top institutional investors include Bank of Montreal Can (0.04%). Company insiders that own Avid Bioservices stock include Joel Mccomb and Mark R Bamforth. View Institutional Ownership Trends for Avid Bioservices.
Which institutional investors are buying Avid Bioservices stock?
How do I buy shares of Avid Bioservices?
Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Avid Bioservices' stock price today?
One share of CDMO stock can currently be purchased for approximately $5.61.
How big of a company is Avid Bioservices?
Avid Bioservices has a market capitalization of $319.77 million and generates $53.62 million in revenue each year. The biopharmaceutical company earns $-21,810,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Avid Bioservices employs 186 workers across the globe.
What is Avid Bioservices' official website?
How can I contact Avid Bioservices?
Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company can be reached via phone at 714-508-6100 or via email at [email protected]
MarketBeat Community Rating for Avid Bioservices (NASDAQ CDMO)
MarketBeat's community ratings are surveys of what our community members think about Avid Bioservices and other stocks. Vote "Outperform" if you believe CDMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDMO will underperform the S&P 500 over the long term. You may vote once every thirty days.
